New Zealand markets closed

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.5400+0.4000 (+12.74%)
At close: 04:00PM EDT
3.8000 +0.26 (+7.34%)
After hours: 07:56PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 37.13M
Enterprise value 41.70M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)6.95
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.39

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 3-38.00%
S&P500 52-week change 322.36%
52-week high 312.0000
52-week low 32.2100
50-day moving average 34.7028
200-day moving average 33.7720

Share statistics

Avg vol (3-month) 3214.22k
Avg vol (10-day) 3240.5k
Shares outstanding 510.49M
Implied shares outstanding 610.49M
Float 86.88M
% held by insiders 127.41%
% held by institutions 13.91%
Shares short (15 Apr 2024) 4510.83k
Short ratio (15 Apr 2024) 42.43
Short % of float (15 Apr 2024) 47.57%
Short % of shares outstanding (15 Apr 2024) 45.34%
Shares short (prior month 15 Mar 2024) 4371.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 302 Apr 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-104.08%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -27.58M
Net income avi to common (ttm)-30.16M
Diluted EPS (ttm)-4.0000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.59M
Total cash per share (mrq)0.49
Total debt (mrq)9.16M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.36
Book value per share (mrq)-1.42

Cash flow statement

Operating cash flow (ttm)-21.66M
Levered free cash flow (ttm)-11.47M